ArriVent BioPharma(AVBP) - 2025 Q1 - Quarterly Results

Exhibit 99.1 ArriVent BioPharma Reports First Quarter 2025 Financial Results Dr. Yao continued, "In the year ahead, we plan to present updated data for firmonertinib in first line EGFR PACC mutant NSCLC, including Progression Free Survival (PFS) and duration of response, and provide our clinical development plan on the PACC program in the second quarter of 2025. We expect topline data in 2025 in our event-driven global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR ex ...